Lifastuzumab, CAS 1615697-16-9

Product Description: Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923.

CAS Number: 1615697-16-9

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Others

Solubility: 10 mM in DMSO

Target: ADC Antibody

• Artikelnummer: MEXHY-P99970-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99970-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated